Fig. 5From: Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinomaThe effect of siGRP78 modified exosomes combined with Sorafenib on the invasion of HCC. a Transwell assay showed the cell invasive ability in sensitive and resistant cancer cells with different treatments (Control, Sorafenib, Exo-scramble siRNA + Sora and Exo-siGRP78 + Sora). Scale bar = 200 μm. b The statistical analysis showed the differences of different treatments normalized to the invasion index of control cells. Data are mean ± SEM (n = 3, *P < 0.05). c Gelatin zymography showed extracellular matrix degradation of HCC by different treatments (1: Control, 2: Sorafenib, 3: Exo-scramble siRNA + Sora and 4: Exo-siGRP78 + Sora). d Western blot showed the expression of MMP2 in Sorafenib sensitive and resistant cancer cells by different treatments. (1: Control, 2: Sorafenib, 3: Exo-scramble siRNA + Sora and 4: Exo-siGRP78 + Sora)Back to article page